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CHROMATOGRAPHY was used to estimate the excretion of metabolites of
ysis an has tryptophan. Anal
i d identification, using both paper and tale columns,
shown that, especiaRy in pathological conditions in man and experimental
animals, there are metabolic blocks at different levels in the complex series of
reactions in the conversion of the tryptophan to nicotinic acid. These blocks
result in the accumulation in the urine of certain metabolites. Some vitamins
take part in the conversion of tryptophan into nicotinic acid and thus form
examples of catalysts which play an essential part in the biological syntheses of
other catalysts. Thus in the absence or deficiency of a vitamin essential for a
reaction such as the conversion of tryptophan into nicotinic acid a metabohc
block will appear.
Recently Auricchio, Quaghariello, Rubino and Vecchione (1959) have exam-
ined the urine of children with different diseases (leukaemia, Hodgkin's disease,
hepatitis, and rickets) and have commented on the presence of abnormal meta-
bolites of the tryptophan-nicotinic acid group. They could not, however, prove
a definiterelationship between the type ofdisease and the abnormal urine.
We are interested in the relationship between tumours of the bladder and the
metabolic by-products from tryptophan degradation and in our preceding work
(Quagliariello, Auricchio, Casale and Tancredi, 1958 ; Fedele, Trancredi and
Riccardi, 1959, 1961) we have discussed the possible aetiology of cancer in
relation to metabohtes oftryptophan.
Bonser, Clayson, Jull and Pirah (1952) have shown that some ortho-amino-
phenols produce cancer of the urinary bladder. Allen, Boyland, Dukes, Horning
and Watson (1957) showed that the twoortho-aminophenols, 3-hydroxykynurenine
and 3-hydroxyanthranilic acid, induced bladder cancer under the same conditions.
Higher concentrations of 3-hydroxyanthranilic acid and kynurenine have been
found in the urine of patients with cancer of the bladder when compared with
urine of either normal subjects or of those with cancer localized in organs other
than the bladder (Boyland and WiUiams, 1955). Perhaps this indicates that a
block at the level of the 3-hydroxyanthranilic oxidase (with subsequent accumu-
lation of 3-hydroxyanthranilic acid and of 3-hydroxykynurenine) is the basis of
tumours of the bladder.
Dunning, Curtis and Mann (1956) in a study of the relationship between diet
and production of cancer by 2-acetylaminofluorene found that cancer of the368 F. QUAGLIARIELLO, F. TANCREDI, L. FEDELE AND C. SACCONE
bladder occurred in almost all of the rats (strain Fisher 344) fed with a diet con-
tainingtryptophan (1-4-4-3 per cent). Thelarge amounts oftryptophan necessary
for the development of cancer suggest that two ortho-aminophenolic derivatives
with carcinogenic activity, 3-hydroxyanthranihc acid and 3-hydroxykynurenine
might be excreted. If 2-acetylaminofluorene caused a biochemical block in the
transformation of these two compounds, it would explain the carcinogenic action
in the bladder of this compound. Quaghariello and his colleagues (1958) have
concluded that rats treated with 2-acetylamino-fluorene have a block at the level
of3-hydroxyanthranilic oxidase in the liver. In the present work the modification
of the tryptophan-nicotinic acid metabohsm by treatment with nicotinamide and
vitamin B6in people with tumours ofthe bladder has been investigated.
EXPERIMENTAL PROCEDURE
Twenty-four hour specimens of urine were acidified with acetic acid (I : 1)
and centrifuged. Charcoal deactivated with 4 per cent by weight of stearic acid
was added to the supernatant and the mixture shaken occasionally for about
5 minutes. The charcoal was filtered off on a smaU Buchner funnel and washed
with water to remove the remaining salts, urea, sugars and aliphatic amino acids.
It was then eluted withphenol solution and water. The eluate was evaporated on
a water-bath under reduced pressure. To ensure complete removal of the phenol
more water was added and the mixture again concentrated. The concentrate
thus obtained was applied directly to paper chromatograms.
For routine use about 10 to 20 ml. of urine was suitable, but there was no
difficulty in using as littleas 5 ml. The amounts of charcoal and phenol used
varied because of variations in the metabolite content of the urine, but a suitable
amount could easily be estimated after some experience had been gained. If
sufficient charcoal had been used the urine filtrate after the initialadsorption was
almost or quite colourless.
For routine examinat'ions one-dimensional descending chromatograms de-
veloped with butanol : acetic acid: water (4 : I: 5, v/v/v) were most suitable.
Chromatograms run under such conditions are adequate for almost all purposes
provided refere'nee standards are run simultaneously. RFvalues can be modified
amongst other things, by a metabohte being displaced by other substances in a
crowded region of the chromatogram, and by variations in the pH of the applied
solution.
Fluorescence under ultra-violet light.-When examined in ultra-violet light
which has passed through a Wood's glass filter many metabohtes are revealed as
characteristic fluorescent spots. Ultra-violet light is also the most convenient
way of revealing the solvent front. Normal urine contains traces of many un-
identified fluorescent substances, some of which may be ofplant origin (from the
diet) rather than true metabolites.
Ninhydrin.-Ninhydrin is of value chiefly for the aromatic amino acids and
also, using a modified reagent and the resulting ultra-violet fluorescence, for
tryptamine derivatives.
Ehrlich's reagent.-This is ofparticular value for the detection of indole deri-
vatives, pyrrole derivatives and aromatic amines. It is convenient to have two
reagents available, differing in acid strength, which will be referred to as the
Cc normal
" and
" strong
" Ehrlich's reagent respectively. The
" normal
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TABLEI.-ChromatographicEvidenceofTryptophanMetabolites in UrineofPatients
with Cancerofthe Bkzdder
3-hydroxy-
anthranilic
acid 3-hydroxy-
Case number Kynurenine kynurenine
1. D. E. + + +
2. A. L. + +
3. G. S. + + +
4. R. A.
5. R. G. + +
6. C. A. + +
7. D. M. + +
8. C. E.
9. Q. F. +
10. C. S.
11. T. P.
12. T. C. +
13. P. L. +
Anthranilic
acid
+ + +
= constant presence and large quantities ; + + = constant presence and small quantities; + =not always present or only in small quantities;
= never present.
TABLE II.-Chromatographic Evidence of Tryptophan Metabolites in Urine of Pa-
tient8 with Cancer of the Bladder, Before'and After Treatment with Nicotinamide
(400 mg./pro diefor 15 day8)
Before nicotinamide treatment
.A- ----N t
Anthra-
nilic
acid
After 15 days of nicotinamide treatment
3-hydroxy-
3-hydroxy- anthra.
kynure- nilic
nine acid
3-hydroxy-
3-hydroxy- anthra- Anthra-
kynure
- nilic nilic
nine acid acid
Kynure.
nine Kynure-
nine Case number
14. T. M.
15. M. G. G.
16. C. A.
17. B. F.
18. C. D.
19. A. S.
20. D. C.
21. B. P.
22. T. V.
23. G. M.
24. L. S.
25. P. L.
26. G. R.
27. D. D. E.
28. A. L.
29. G. S.
30. G. G.
31. D'A. M.
32. S. E.
33. C. M.
34. C. D.
35. B. S.
36. P. V.
+ + + = constant presence and large quantities; + +
= constant presence and sman quan- tities ; +
= not always present or only in small quantities;
= never present.Before vitamin B6 treatment
11 A
A
After 15 days of vitamin B. treatment
r-. A
I
3-hydroxy-
3-hydroxy- anthra. Anthra.
Kynure- kynure- nilic nilic
nine nine acid acid
Before vitamin B. treatment
I -.A-
I
After 15 days of nicotinamide and
vitamin B. treatment
A
I
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TABLE III.-Chromatographic Evidence of Tryptophan Metabolites in the Urine of
Patients with Cancer of the Bladder, Before and .4fter Treatment with Vitamin B6
(400 mg./pro diefor I5 days)
3-hydroxy-
3-hydroxy- anthra.
Kynure- kynure- nilic
nine nine acid
Anthra-
nilic
acid Case number
37. E. A.
38. D. G.
39. N. L.
40. D. S.
+ + + = constant presence and large quantities; + +
= constant presence and small quan-
tities ; +
= not always present or only in small quantities;
= never present.
TABLE IV.-Chromatographic Evidence of Tryptophan Metabolite8 in the Urine of
Patient8 with Cancer of the Bladder, Before and A er Treatment with Nicotinamide
and vitamin B6 (200 mg. + 200 mg./pro diefor 15 day8)
3-hydroxy-
anthra- Anthra-
nilic nilic
acid acid
3-hydroxy-
3-hydroxy- anthra- Anthra-
kynure- nilic nilic
nine acid acid
3-hydroxy-
Kynure- kynure-
nine nine
I + + +
I + +
I + +
Kynure-
nine Case number
41. P. M.
42. C. M.
43. S. A.
44. A. G.
45. D'A. V.
46. D. G.
47. S. M.
+ + + constant presence and large quantities; + + constant presence and small quan- tities ; +not always present or only in small quantities; = never present.
is a 2 per cent (w/v) solution ofp-dimethylaminobenzaldehyde in approximately
I -3N-HCI. The
" strong
" reagent is a 2 per cent (w/v) solution of the aldehyde
in approximately 6 N-HCI. After spraying the papers are allowed to dry at room
temperature. With the
" normal
" reagent, aromatic amines give a yenow colour
immediately, whereas colours from indole derivatives may take some time to form.
At the pH of the
" strong
" reagent derivatives of aromatic amines are formed
but remain colourless, whereas indole derivatives including indican, give a colour
rapidly. It is thus possible to distinguish the two types of compounds even if
present in the same spot. Ultimately the picture obtained with both reagents is
the same.
Ammoniacal silver nitrate.-The papers are sprayed and anowed to dry at
room temperature. The reagent is of special value in detecting substances con-
taining readily oxidizable groups such as o-aminophenol or catechol derivatives.
These rapidlygive black or brown-black spots. Many other substances will react,
but more slowly.371 TRYPTOPHAN-NICOTINIC ACID METABOLISM
Urine from 47 patients with cancer of the bladder was coflected and analysed
every other day for 20 days. At the end of this time 23 of these patients were
given 400 ma. per day of nicotinamide (Nicotinamide
" Lepetit ") by parenteral
injection for 15 days. Four other patients were injected with 400 mg. Vitamin B. (Benadon
" Roche ") per day for 15 days. Seven patients were treated with both
vitamin B6 (200 mg.) and nicotinamide (200 mg.). In some patients the studies
were continued after surgical removal of the tumouirs.
RESULTS
In the urine from 44 of the patients 3-hydroxyanthranilic acid was present
kynurenine and anthranilic acid were present in 35 and 31 of these cases respec-
tively. 3-Hydroxykynurenine was found in only 11 patients. Additional meta-
bolites such as acetylkynurenine, anthranilic acidglueuronide, kynurenic acid and
xanthurenic acid were occasionally present.
In 3patients3-hydroxyanthranilic acid was never detected butonlykynurenine
and some of its derivatives.
In 14 of the 23 patients treated with nicotinamide there was a gradual dis-
appearance of the 3-hydroxyanthranilic acid often with a complete change in the
chromatographic pattern. In 2 patients the nicotinamide treatment, begun only aftersurgical operation, caused the excretion ofthe metabolites ofthetryptophan-
nicotinic acid group to return to normal.
Vitamin B6was given to four patients whose urine contained large amounts of
3-hydroxykynurenine. Normal functioning of the excretory system was obtained
only in one case. Another 7 patients were treated with both nicotinamide and
vitamine BW but normal excretion was obtained in only 3 cases, probably because
only a half-dose of vitamin B6 and nicotinamide was administered.
(1) Of the three patients who never excreted 3-hydroxyanthranilic acid,
biopsies showed that two did not have cancer of the bladder.
(2) All 4-i ofthe casesinvestigated were followed for 20days. In somepatients
the presence of 3-hydroxyanthranilic acid in the urine was always detectable
in others the excretion of this metabolite was not constant.
(3) In recent studies by others (Benassi and Perissinotto, 1959, 1960) 3-hydro- xyanthranilic acid has not been found, although a large number of cases were
examined.
(4) In 13 of the subjects examined we have followed the urinary excretion of
the metabolites oftryptophan even after surgical removal of the tumour and we
have not found that the excretory products have returned to normal. This is
important, because it indicates a dangerous and permanent metabolic block.
(5) The nicotinamide treatment appears to cause normal metabolism of tryp- tophan. This treatment was suggested by ourprevious researches which indicated
the probable role of DPN in the 3-hydroxyanthranilic acid oxidation.
DISCUSSION'
From our results it is evident that in different diseased conditions the normal
mechanisms for degradation oftryptophan are altered and that some metabolites
of the tryptophan-nicotinic acid group accumulate in the urine. However, with
paper chromatography it is not always possible to demonstrate a pattern which372 F. QUAGLIARIELLO, F. TANCREDI, L. FEDELE AND C. SACCONE
differs according to the disease. We feel, however, that there is a characteristic
change in the excretoryproducts ofpeople afflicted with cancer ofthe bladder.
In agreement with our earher studies (Fedele, et al., 1959, 1961 ; Quagliariello
et al., 1958) the researches of Boyland and WiRiams (1955), and experiments of
Tompsett (1959), the results showthat3-hydroxyanthranilic acidisusuallypresent
in the urine along with other metabohtes of the tryptophan-nicotinic acid group
-kynurenine and anthranihc acid-in bladder cancer patients.
After our studies and those of others we have cited, we cannot consider re-
search regarding the correlation between blocks in the tryptophan nicotinic acid
metabohsm and cancer of the bladder as finished. However, it appears more evi-
dent that there is arelationship between metabolites ofthetryptophan and cancer
of the bladder.
SUMMARY
Urine frompatients with bladder cancerusually contains 3-hydroxyanthranihc
acid,kynurenine and anthranihc acid. The excretion of3-hydroxyanthranilic acid
is reduced by treatment with large doses of nicotinamide.
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